S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Why Your IRA Could Crash on January 16th? (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
Why Your IRA Could Crash on January 16th? (Ad)
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Why Your IRA Could Crash on January 16th? (Ad)
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Why Your IRA Could Crash on January 16th? (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
Why Your IRA Could Crash on January 16th? (Ad)
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Why Your IRA Could Crash on January 16th? (Ad)
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Why Your IRA Could Crash on January 16th? (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
Why Your IRA Could Crash on January 16th? (Ad)
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Why Your IRA Could Crash on January 16th? (Ad)
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Why Your IRA Could Crash on January 16th? (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
Why Your IRA Could Crash on January 16th? (Ad)
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Why Your IRA Could Crash on January 16th? (Ad)
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
NASDAQ:DVAX

Dynavax Technologies - DVAX Stock Forecast, Price & News

$12.72
+0.18 (+1.44%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$12.29
$12.80
50-Day Range
$9.93
$13.29
52-Week Range
$7.26
$17.48
Volume
1.22 million shs
Average Volume
1.65 million shs
Market Capitalization
$1.62 billion
P/E Ratio
6.14
Dividend Yield
N/A
Price Target
$23.67

Dynavax Technologies MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
86.1% Upside
$23.67 Price Target
Short Interest
Bearish
12.33% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.59
Upright™ Environmental Score
News Sentiment
0.44mentions of Dynavax Technologies in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$650,984 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From $1.84 to ($0.39) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

387th out of 1,034 stocks

Pharmaceutical Preparations Industry

170th out of 502 stocks

DVAX stock logo

About Dynavax Technologies (NASDAQ:DVAX) Stock

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

Receive DVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dynavax Technologies and its competitors with MarketBeat's FREE daily newsletter.

DVAX Stock News Headlines

Dynavax to Present at Two Upcoming Investor Conferences
DVAX Dynavax Technologies Corporation
Dynavax Technologies (NASDAQ: DVAX)
Why Dynavax Stock Popped by Over 5% Today
Is Dynavax Technologies (DVAX) Stock Undervalued Right Now?
See More Headlines
Receive DVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dynavax Technologies and its competitors with MarketBeat's FREE daily newsletter.

DVAX Company Calendar

Last Earnings
11/04/2021
Today
12/03/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/27/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:DVAX
CUSIP
26815810
Employees
311
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$23.67
High Stock Price Forecast
$28.00
Low Stock Price Forecast
$21.00
Forecasted Upside/Downside
+86.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$76.71 million
Pretax Margin
44.58%

Debt

Sales & Book Value

Annual Sales
$439.44 million
Cash Flow
$1.01 per share
Book Value
$3.92 per share

Miscellaneous

Free Float
115,707,000
Market Cap
$1.62 billion
Optionable
Optionable
Beta
1.34

Social Links


Key Executives

  • Mr. Ryan SpencerMr. Ryan Spencer (Age 44)
    CEO & Director
    Comp: $1.19M
  • Mr. David F. NovackMr. David F. Novack (Age 60)
    Pres & COO
    Comp: $969.98k
  • Ms. Kelly MacDonaldMs. Kelly MacDonald (Age 38)
    Sr. VP & CFO
    Comp: $553.42k
  • Mr. Michael S. Ostrach (Age 70)
    Advisor
    Comp: $728.34k
  • Dr. Robert JanssenDr. Robert Janssen (Age 68)
    Chief Medical Officer and Sr. VP of Clinical Devel., Medical & Regulatory Affairs
    Comp: $817.17k
  • Mr. Justin BurgessMr. Justin Burgess
    Principal Accounting Officer & Controller
  • Mr. Jeff P. Coon (Age 59)
    CHRO and Sr. VP of HR & Admin.
  • Nicole Arndt
    Sr. Mang. of Investor Relations
  • Mr. John Slebir
    Sr. VP & Gen. Counsel
  • Ms. Meg Smith
    VP Sales & Operations













DVAX Stock - Frequently Asked Questions

Should I buy or sell Dynavax Technologies stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DVAX shares.
View DVAX analyst ratings
or view top-rated stocks.

What is Dynavax Technologies' stock price forecast for 2023?

3 Wall Street research analysts have issued 12 month target prices for Dynavax Technologies' stock. Their DVAX share price forecasts range from $21.00 to $28.00. On average, they expect the company's share price to reach $23.67 in the next year. This suggests a possible upside of 86.1% from the stock's current price.
View analysts price targets for DVAX
or view top-rated stocks among Wall Street analysts.

How have DVAX shares performed in 2022?

Dynavax Technologies' stock was trading at $14.07 at the beginning of 2022. Since then, DVAX stock has decreased by 9.6% and is now trading at $12.72.
View the best growth stocks for 2022 here
.

Are investors shorting Dynavax Technologies?

Dynavax Technologies saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 15,730,000 shares, an increase of 9.2% from the October 31st total of 14,400,000 shares. Based on an average daily volume of 1,850,000 shares, the short-interest ratio is presently 8.5 days.
View Dynavax Technologies' Short Interest
.

When is Dynavax Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our DVAX earnings forecast
.

How were Dynavax Technologies' earnings last quarter?

Dynavax Technologies Co. (NASDAQ:DVAX) released its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of $0.05 by $0.29. The biopharmaceutical company earned $108.27 million during the quarter, compared to analysts' expectations of $77.30 million. Dynavax Technologies had a trailing twelve-month return on equity of 90.54% and a net margin of 44.35%. During the same period in the previous year, the firm posted ($0.15) EPS.

What is Eddie Gray's approval rating as Dynavax Technologies' CEO?

13 employees have rated Dynavax Technologies Chief Executive Officer Eddie Gray on Glassdoor.com. Eddie Gray has an approval rating of 59% among the company's employees. This puts Eddie Gray in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 61.0% of employees surveyed would recommend working at Dynavax Technologies to a friend.

What other stocks do shareholders of Dynavax Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (bmrn), (MDVN) (MDVN), Incyte (incy), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Matinas BioPharma (MTNB), First Solar (FSLR), Inovio Pharmaceuticals (INO) and ADMA Biologics (ADMA).

What is Dynavax Technologies' stock symbol?

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

Who are Dynavax Technologies' major shareholders?

Dynavax Technologies' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.50%), Federated Hermes Inc. (9.89%), State Street Corp (8.05%), Vanguard Group Inc. (6.40%), Chicago Capital LLC (4.59%) and Bain Capital Life Sciences Investors LLC (4.24%). Insiders that own company stock include Andrew A F Hack, David F Novack, David F Novack, Francis Cano, Justin Burgess, Robert Janssen and Ryan Spencer.
View institutional ownership trends
.

How do I buy shares of Dynavax Technologies?

Shares of DVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Dynavax Technologies' stock price today?

One share of DVAX stock can currently be purchased for approximately $12.72.

How much money does Dynavax Technologies make?

Dynavax Technologies (NASDAQ:DVAX) has a market capitalization of $1.62 billion and generates $439.44 million in revenue each year. The biopharmaceutical company earns $76.71 million in net income (profit) each year or $2.07 on an earnings per share basis.

How many employees does Dynavax Technologies have?

The company employs 311 workers across the globe.

How can I contact Dynavax Technologies?

Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The official website for the company is www.dynavax.com. The biopharmaceutical company can be reached via phone at (510) 848-5100, via email at ir@dynavax.com, or via fax at 510-848-1327.

This page (NASDAQ:DVAX) was last updated on 12/3/2022 by MarketBeat.com Staff